Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease

Pharmacognosy Reviews

Volumn 4, Issue 7, 2010, Pages 32-41

  Tassell, Mary ^a   Kingston, Rosari ^b   Gilroy, Deirdre ^c   Lehane, Mary ^d   Furey, Ambrose ^a  

^a Munster Technological University   (Ireland)

^b Churchcross Co Cork   (Ireland)

^c CIT   (Ireland)

^d Athletic Rehabilitation Therapy Ireland   (Ireland)

Author keywords

Cardiovascular disease; Crataegus; hawthorn; whitethorn

Indexed keywords

ACETYLCYSTEINE; BIOFLAVONOID; CAMPHOR; CRALONIN; CRATAEGUS EXTRACT; DIGITALIS; DIGOXIN; GLUTATHIONE; HOMEOPATHIC AGENT; HYPERIN; PLANT MEDICINAL PRODUCT; PROANTHOCYANIDIN; UNCLASSIFIED DRUG; VASODILATOR AGENT; VITEXIN 2 RHAMNOSIDE;

ABSENCE OF SIDE EFFECTS; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CRATAEGUS; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HERB DRUG INTERACTION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NONHUMAN; OPTIMAL DRUG DOSE; REVIEW; TREATMENT OUTCOME;

ACACIA CONSTRICTA; CRATAEGUS;

EID: 77955681208     PISSN: None     EISSN: 09737847     Source Type: Journal    
DOI: 10.4103/0973-7847.65324     Document Type: Review

References (72)

1. Albarouki E, Peterson A, Molecular and morphological characterization of Crataegus L. species (Rosaceae) in southern Syria. Botanical Journal of the Linnean Society; 2007.
2. British, H.F. British Heart Foundation. Statistics. 2006 3rd November; Available froml http://www.heartstats.org/datapage. asp?id=713. [cited in 2007].
3. World, H.O. World Health Organisation Website. Available from: http://www.who.int/topics/cardiovascular-diseasees/en/. [cited in 2007].
4. National S. Heart disease leading cause of death in England and Wales. Health Statistics Quarterly;2006.
5. Herbal Medicines Association, B., British Herbal Pharmacopoeia. Bournemouth: British Herbal Medicines Association;1984.
6. Mills S, Bone K. Principles and Practice of Phytotherapy. London: Churchill Livingstone;2000.
7. Zick SM, Gillespie B, Aaronson K. The Effect of Crataegus oxyacantha special extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. European Journal of Heart Failure; 2008. p. 387-393
8. American and H. Association. Coronary Risk Profi le. Available from: http://www.americanheart.org/presenter. jhtml?identifi er=4528. [cited in 2008].
9. Wold RS, Lopez ST, Yau CL, Butler LM, Pareo-Tubbeh SL, Waters DL, et al. Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. J Am Diet Assoc 2005;105:54-63.
10. Miller LG. Selected Clinical Considerations Focussing on Known or Potential Drug-Herb Interactions. Archives of Internal Medicine 1998;158:2200-2211
11. Culpepper N. The British Herbal and Family Physician. Halifax: Nicholson and Co;1820.
12. Kingston R. A phyotchemical analysis of selected constituents of Crataegus fl os and fruct. to determine whether ethanol, whiskey and brandy solvents affect the chemical constituent profi le of the herbal preparations 2007, Scottish School of Herbal Medicine.
13. Vanhaelen M, Vanhaelen-Fastre R. TLC-densitometric determination of 2,3-cis-procyanidin monomer and oligomers from hawthorn (Crataegus laevigata and C. monogyna). J Pharm Biomed Anal 1989;7:1871-1875
14. Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, et al. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med 2002;113:71-88.
15. Long SR, Carey RA, Crofoot KM, Proteau PJ, Filtz TM. Effect of hawthorn (Crataegus oxycantha) crude extract and chromatographic fractions on multiple activities in a cultured cardiomyocyte assay. Phytomedicine 2006;13:643-650
16. Ling S. Effects of four medicinal herbs on human vascular endothelial cells in culture. Int Jrnl cardio;2007.
17. Brixius K, Willms S, Napp A, Tossios P, Ladage D, Bloch W, et al. Crataegus special extract WS 1442 induces an endothelium-dependent, NO-mediated vasorelaxation via eNOS-phosphorylation at serine 1177. Cardiovasc Drugs Ther 2006;20:177-184
18. Quettier-Deleu C, Voiselle G, Fruchart JC, Duriez P, Teissier E, Bailleul F, et al. Hawthorn extracts inhibit LDL oxidation. Pharmazie 2003;58:577-581
19. Zhang Z. Hypercholesterolaemic activity of Hawthorn fruit is mediated by regulation of cholesterol 7? Hydroxylase and acyl CoA: cholesterol acyltransferase. Food Res Int 2002;35:885-891
20. Vierling W, Brand N, Gaedcke F, Sensch KH, Schneider E, Scholz M. Investigation of the pharmaceutical and pharmacological equivalence of different Hawthorn extracts. Phytomedicine 2003;10:8-16.
21. Tsuyaki RT. β-Blockers for congestive heart failure. What is the current consensus? Drugs Aging 2000;16:1-7.
22. Kim SH, Kang KW, Kim KW, Kim ND. Procyanidins in crataegus extract evoke endothelium-dependent vasorelaxation in rat aorta. Life Sci 2000;67:121-131
23. Guo C. Antioxidant activities of peel, pulp and seed fractions of common fruits as determined by FRAP assay. Nut Res 2003;23:1719-1726
24. Zhang Z. Characterisation of antioxidants present in Hawthorn fruits. J Nutr Biol 2000;12:144-152
25. Bahorun T, Gressier B, Trotin F, Brunet C, Dine T, Luyckx M, et al. Oxygen species scavenging activity of phenolic extracts from hawthorn fresh plant organs and pharmaceutical preparations. Arzneimittelforschung 1996;46:1086-1089
26. Bleske BE. Evaluation of Hawthorn extract on immodulatory biomarkers in a pressure overload model of heart failure. Med Sci Mon 2007;13:255-258
27. Orhan I. HPLC Quantifi cation of vitexine-2"-O-rhamnoside and hyperoside in three crataegus species and their antimicrobial and antiviral activities. Chromato Suppl 2007;66:153-7.
28. Chang WT, Dao J, Shao ZH. Hawthorn: Potential Roles in Cardiovascular Disease. Amer Jrnl Chin Med 2005;33:1-10.
29. Chang Q, Zuo Z, Ho WK, Chow MS. Comparison of the pharmacokinetics of hawthorn phenolics in extract versus individual pure compound. J Clin Pharmacol 2005;45:106-112
30. Liang M, Xu W, Zhang W, Zhang C, Liu R, Shen Y, et al. Quantitative LC/MS/MS method and in vivo pharmacokinetic studies of vitexin rhamnoside, a bioactive constituent on cardiovascular system from hawthorn. Biomed Chromatogr 2007;21:422-429
31. Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med 2003;114:665-674
32. Hellenbrecht D, Randomised, placebo controlled study with crataegus on exercise tests and challenge by catecholamines. Eur J Pharmacol 1990;183:525-526
33. Zapfe jun G. Clinical effi cacy of crataegus extract WS 1442 in congestive heart failure NYHA class II. Phytomedicine 2001;8:262-266
34. Habs M. Prospective, comparative Cohort Studies and Their Contribution to the benefi t Assessments of Therapeutic Options: Heart Failure Treatment with and without Hawthorn Special Extract WS 1442. Forsch Komplementarmed Klass Naturheilkd 2004;11:36-39
35. Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M The effi cacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail 2008;10: 1255-1263
36. Tauchert M. Effi cacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 2002;143:910-915
37. Degenring FH, Suter A, Weber M, Saller R. A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II. Phytomedicine 2003;10:363-369
38. Schroder D, Weiser M, Klein P. Effi cacy of a homeopathic Crataegus preparation compared with usual therapy for mild (NYHA II) cardiac insuffi ciency: results of an observational cohort study. Eur J Heart Fail 2002;5:319-326
39. Furey A, Tassell M. Towards a systematic scientifi c approach in the assessment of effi cacy of an herbal preparation: Hawthorn (Crataegus spp.). Eur J Heart Fail 2008;10:1153-1157
40. Asgary S, Naderi GH, Sadeghi M, Kelishadi R, Amiri M. Antihypertensive effect of Iranian Crataegus curvisepala Lind: a randomized, double-blind study. Drugs Exp Clin Res 2004;30:221-225
41. Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M. Survival and prognosis: investigation of Crataegus extract WS 1442 in congestive heart failure (SPICE)-rationale, study design and study protocol. Eur J Heart Fail 2000;2:431-437
42. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991;337:867-872
43. ESCOP, Expanded Commision E monographs; 1994.
44. Brown D. High Dose Hawthorn Extract for Advanced Congestive Heart Failure. Herbalgram 2003;57:24-25,28.
45. Association BM. British National Formulary. Mehta DK, editors. 2005.
46. Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M The effi cacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail 2008;10: 1255-1263
47. Belz GG, Butzer R, Gaus W, Loew D. Camphor-Crataegus berry extract combination dose-dependently reduces tilt induced fall in blood pressure in orthostatic hypotension. Phytomedicine 2002. 9: p. 581-588.
48. Belz GG, Loew D. Dose-response related effi cacy in orthostatic hypotension of a fi xed combination of D-camphor and an extract from fresh crataegus berries and the contribution of the single components. Phytomedicine 2003;10:61-67
49. Yoo KM. Relative antioxidant and cytoprotective activities of common herbs. Food Chem 2007;106:929-936
50. Cui T, Nakamura K, Tian S, Kayahara H, Tian YL. Polyphenolic content and physiological activities of Chinese hawthorn extracts. Biosci Biotechnol Biochem 2006;70:2948-2956
51. Ljubuncic P, Portnaya I, Cogan U, Azaizeh H, Bomzon A. Antioxidant activity of Crataegus aronia aqueous extract used in traditional Arab medicine in Israel. J Ethnopharmacol 2005;101:153-161
52. Schüssler M, Hölzl J, Fricke U. Myocardial effects of flavonoids from Crataegus species. Arzneimittelforschung 1995;45:842-845
53. Walker AF, Marakis G, Simpson E, Hope JL, Robinson PA, Hassanein M, et al. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. Br J Gen Pract 2005;56:437-443
54. Rigelsky JM, Sweet BV. Hawthorn: pharmacology and therapeutic uses. Am J Health Syst Pharm 2002;59:417-422
55. Fong HH, Bauman JL. Hawthorn. J Cardiovasc Nurs 2002;16:1-8.
56. Daniele C, Mazzanti G, Pittler MH, Ernst E. Adverse-event profi le of Crataegus spp.: a systematic review. Drug Saf 2006;29: 523-535
57. Thorne R. Crataegus oxyacantha. Alt Med Rev 1998;3:138-139
58. Loew D. Phytotherapy in Heart Failure. Phytomedicine 1997;4:267-271
59. Felker GM, O'Connor CM. Inotropic therapy for heart failure:An evidence based approach. American Heart J 2001;42:393-401.
60. Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M. Survival and prognosis: investigation of Crataegus extract WS 1442 in congestive heart failure (SPICE)-rationale, study design and study protocol. Eur J Heart Fail 2000;2:431-437
61. Kernan WN, Castellsague J, Perlman GD, Ostfeld A. Incidence of hospitalization for digitalis toxicity among elderly Americans. Am J Med 1994;96:426-431
62. Baughman KL, Bradley DJ. Hawthorn extract: is it time to turn over a new leaf? Am J Med 2003;114:700-701
63. Tankanow R, Tamer HR, Streetman DS, Smith SG, Welton JL, Annesley T, et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol 2003;43:637-642
64. Kendler BS. Recent nutritional approaches to the prevention and therapy of cardiovascular disease. Prog Cardiovasc Nurs 1997;12:3-23.
65. Spinella M. The importance of pharmacological synergy in psychoactive herbal medicines-Herbal Synergy Review. Alternative Medicine Review; 2002. p. 130-137
66. Skegert M. Phenols, procyanidins, fl avones and fl avonols in some plant materials and their antioxidant activities. Food Chem 2005;89:191-198
67. Cirico TL, Omaye ST. Additive or synergetic effects of phenolic compounds on human low density lipoprotein oxidation. Food Chem Toxicol 2005;44:510-516
68. Sokol-Letowska A, Oszmianski J, Wojdylo A. Antioxidant activity of the phenolic compounds of hawthorn, pine and skullcap. Food Chem 2006;103:853-859
69. Zapatero JM. Selections from current literature: effects of hawthorn on the cardiovascular system. Fam Pract 1999;16:534-538
70. Cleland JGF. Response from editor to letter to the editor: Alternative approaches to the management of heart failure: Editors response. Eur J Heart Fail 2004;6:517-518
71. Wojdyto A, Oszmianski J. Infl uence of polyphenols isoalted from Scutellaria baiacalensis Georgi and Crataegus oxyacantha on the oxidative stability of cholesterol in butter stored in various conditions. Euro Food Res Techno 2006;224:635-642
72. Fan C, Yan J, Qian Y, Wo X, Gao L. Regulation of lipoprotein lipase expression by effect of hawthorn fl avonoids on peroxisome proliferator response element pathway. J Pharmacol Sci 2005;100:51-58